Trial Profile
STroke secondary prevention with catheter ABLation and EDoxaban for patients with non-valvular atrial fibrillation
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2019
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms STABLED
- 19 Jul 2019 Status changed from not yet recruiting to discontinued.
- 08 Feb 2019 Trial design presented at the International Stroke Conference 2019
- 05 Mar 2018 New trial record